« Back
Home /
ST 2825

ST 2825

Item no.	HY-50937-100mg
Manufacturer	MedChem Express
CASRN	894787-30-5
Amount	100 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 mg 25 mg 50 mg 5 mg
Category	Metabolism Diabetes Glucose Homeostasis Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.92
Citations	[1]Loiarro M, et al. Pivotal advance: inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound. J Leukoc Biol. 2007 Oct;82(4):801-10.\|[2]Fantò N, et al. Design, Synthesis, and In Vitro Activity of Peptidomimetic Inhibitors of Myeloid Differentiation Factor 88. J Med Chem. 2008 Mar 13;51(5):1189-202.\|[3]Van Tassell BW, et al. Pharmacologic Inhibition of Myeloid Differentiation Factor 88 (MyD88) Prevents Left Ventricular Dilation and Hypertrophy After Experimental Acute Myocardial Infarction in the Mouse. J Cardiovasc Pharmacol. 2010 Apr;55(4):385-90.\|[4]Zhang HS, et al. Inhibition of myeloid differentiation factor 88(MyD88) by ST2825 provides neuroprotection after experimental traumatic brain injury in mice. Brain Res. 2016 Jul 15;1643:130-9.\|[5]Wang N, et al. Myeloid differentiation factor 88 is up-regulated in epileptic brain and contributes to experimental seizures in rats. Exp Neurol. 2017 Sep;295:23-35.\|[6]Brad Griesenauer, et al. ST2/MYD88 signaling is a therapeutic target alleviating murine acute graft-versus-host disease sparing T regulatory cell function. Indiana University. May 2018.
Smiles	O=C(N([C@H]1C(N)=O)[C@@](SCC1)([H])C2)[C@]2(CCC3)N3C(CC4=CC=C(C=C4)NC(COC(C(Cl)=C5)=CC=C5Cl)=O)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	COVID-19-immunoregulation
Manufacturer - Targets	MyD88
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	591.51
Product Description	ST 2825 is a specific MyD88 dimerization inhibitor. ST2825 interferes with recruitment of IRAK1 and IRAK4 by MyD88, causing inhibition of IL-1β-mediated activation of NF-κB transcriptional activity[1][2].
Manufacturer - Research Area	Inflammation/Immunology
Solubility	DMSO: 100 mg/mL (ultrasonic)
Manufacturer - Pathway	Immunology/Inflammation
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-50937-100mg-safety-datasheet.pdf